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Sir,
Rhabdomyolysis is a rare adverse effect reported with daptomy-
cin use. Here we report the first case of creatinine phosphokinase
(CPK) elevation with rhabdomyolysis developing during the
co-administration of daptomycin and pegylated interferon a-2b
and ribavirin.
We describe the case of a patient with a history of intravenous
drug abuse and hepatitis C admitted to our division because of
fever and pain in the right gluteal region.
The patient’s general condition was poor, but his physical
examination was unremarkable, except for the presence of a
right gluteal abscess. The patient had been taking pegylated
interferon a-2b and ribavirin for 5 months without reporting
side effects. On admission, liver function tests were within
normal limits, serum CPK level was slightly elevated (518 U/L;
normal values 39–308 U/L), lactate dehydrogenase (LDH) was
580 U/L (normal values 240–480 U/L), serum creatinine was
1.6 mg/dL and estimated CLCR was 124.8 mL/min. The white
blood cell (WBC) count showed neutrophil leucocytosis (WBC
11580 cells/mm3, 87.1% neutrophils) and a low platelet count
(72000 cells/mm3). All other laboratory findings were within
normal limits. Hepatitis C virus (HCV) RNA viral load was
undetectable. Blood cultures were performed.
The patient was started on empirical antibiotic therapy with
levofloxacin (750 mg once daily intravenously) and piperacillin/
tazobactam (4.5 g every 6 h intravenously). Due to lack of
improvement of symptoms and fever after 48 h, levofloxacin
was switched to daptomycin (500 mg daily intravenously). The
second dose was administered, by mistake, 4 h before it should
have been. Five days after admission, after only two doses of
daptomycin, the patient suddenly complained of weakness and
diffuse aches in the proximal thighs and arms. Serum CPK
levels were very high (12933 U/L) and further elevations in
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT), 371 and 67 IU/L, respectively, were also noted. A urine
drug screen was performed to rule out damage related to illicit
substance use, and the results were negative. Blood cultures
were positive for methicillin-resistant Staphylococcus aureus
(MRSA). Suspecting daptomycin-induced rhabdomyolysis, treat-
ment was switched to linezolid (600 mg twice daily intrave-
nously) and meropenem (1 g every 8 h intravenously). The
patient was hydrated (2 L/day) to preserve renal function, and
this was strictly monitored throughout the course; urinalysis
was positive for myoglobin. Although daptomycin had been
interrupted, CPK levels and AST/ALT levels continued to increase
for 5 days after and on the sixth day the CPK level was 45257 U/L,
LDH was 6892 U/L and AST/ALT was 980/107 IU/L. The CPK level
slowly decreased 10 days after discontinuation of daptomycin.
Daptomycin is a lipopeptide antibiotic approved for the treat-
ment of complicated skin and soft-tissue infections caused by
susceptible Gram-positive strains, including MRSA and
vancomycin-susceptible Enterococcus faecalis. Daptomycin has
also been approved for S. aureus bloodstream infection and for
the treatment of right-sided endocarditis caused by methicillin-
susceptible S. aureus and MRSA. The main side effect is skeletal
muscle toxicity. In clinical trials, 2.8% of subjects experienced
elevations in CPK level, and 0.2% of the study population
reported myopathy.1 This condition is favoured in obesity, dia-
betes mellitus, chronic renal failure, bacterial sepsis, electrolyte
abnormalities and concomitant treatment with statins
(3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors).2
Few cases of daptomycin-induced rhabdomyolysis have been
described in the literature.2,3 Only two reports described patients
with early onset rhabdomyolysis related to daptomycin use.4
Here, we report the second case of onset after only two doses
of daptomycin, with a CPK level of 45257 U/L. To our knowledge,
this is the first case of daptomycin-induced rhabdomyolysis in a
patient receiving pegylated interferon a-2b and ribavirin for
HCV-related hepatitis. Interferon a-2b, but not ribavirin, has
been associated with rhabdomyolysis.5 Our patient already had
increased CPK levels at presentation, but had never had any
sign or symptom of myopathy, suggesting that hepatitis C
therapy had been well tolerated. Thus, daptomycin was adminis-
tered despite increased CPK levels. We believe that a prominent
role in daptomycin toxicity was played by the short interval
between the two doses (by mistake); according to the
literature, dosing frequency seems to have a more direct effect
upon skeletal muscle than peak plasma concentration.6,7 Our
patient also had MRSA bacteraemia. Bacterial sepsis has been
associated with the development of rhabdomyolysis, and in
this case it may have functioned as a predisposing factor.
In conclusion, given the temporal relationship between dap-
tomycin initiation and elevation in CPK level, we identified dapto-
mycin as the main cause of the patient’s myopathy. Therefore,
we recommend close monitoring of CPK and symptoms of myo-
pathy in all patients started on this drug. Moreover, we think that
the concomitant use of pegylated interferon a-2b most likely
induced the adverse activity of daptomycin. It may be advisable,
given the limited experience, to interrupt therapy with interferon
during daptomycin treatment.
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Sir,
Atazanavir is a widely used protease inhibitor with a favourable
pharmacokinetic profile, allowing once-daily dosing with or
without ritonavir boosting. It is both a substrate and a competi-
tive inhibitor of cytochrome P450 3A4 and also a competitive
inhibitor of the bilirubin-conjugating enzyme UDP glucuronyl
transferase 1A1. Atazanavir is metabolized and eliminated pri-
marily by the liver and its metabolites are excreted in the bile.
In healthy subjects, renal elimination of unchanged atazanavir
was only 7% of the administered daily dose. A population phar-
macokinetic sub-study, derived from study AI424007 in naive
patients receiving 200, 400 or 500 mg of atazanavir once daily
(a clinical Phase III trial of atazanavir efficacy, safety and toler-
ability), demonstrated the relationship between plasma exposure
(area under the curve and trough plasma concentration) and
both safety (hyperbilirubinaemia) and viral efficacy.1 Renal lithia-
sis is a commonly reported side effect of atazanavir, with at least
30 cases identified by the FDA between 2002 and 2007.2 One
case of choledocholithiasis-associated atazanavir in a 47-year-
old HIV-infected African female 6 weeks after the initiation of
an atazanavir-containing regimen has been published recently.3
Six additional cases of cholelithiasis occurring within months to
years after initiation of atazanavir are recorded in the French
National Pharmacovigilance Database. A cholecystectomy was
performed in four of these cases and atazanavir was identified
in biliary stones in two cases. Here we report a new case. The
patient signed a written informed consent for publication.
A 64-year-old HIV-1-infected male who was immunovirologi-
cally stable (plasma HIV-1 RNA ,20 copies/mL and CD4 cells
525/mm3; CD4 cells¼33% of white blood cells) and showed
good treatment adherence was hospitalized in July 2010 for
exploration of a right flank pain experienced for several
months. Ultrasonography revealed a huge gallstone (weight
13 g, diameter 25 mm), which was subsequently extracted
from the common bile duct by laparoscopic cholecystectomy.
After solubilization of the stone in acid aqueous solvent, the
brown-coloured solution obtained was analysed to determine
antiretroviral drug concentrations using ultra-performance
liquid chromatography-mass spectrometry/mass spectrometry.4
The atazanavir concentration determined in the gallstone recov-
ered from this patient, who had switched from atazanavir/ritona-
vir to a darunavir/ritonavir+tenofovir/emtricitabine (300/200 mg
once daily)-containing regimen 1 year previously, was approxi-
mately 6.0 mg/g. In the same sample, darunavir and ritonavir
concentrations were 0.9 and 0.13 mg/g, respectively, while
neither tenofovir nor emtricitabine was found. Since 1993, this
patient had received 19 successive antiretroviral regimens,
including six protease inhibitors, seven nucleoside reverse tran-
scriptase inhibitors and two non-nucleoside reverse transcriptase
inhibitors in combination. He had no history of opportunistic infec-
tion, and liver and renal functions were normal. The plasma viral
load was undetectable for the last 9 years except for two treat-
ment interruptions. Cumulative durations of protease inhibitor
therapies were approximately 5 years for indinavir and 5 years
for atazanavir. One year after starting unboosted indinavir, the
patient developed a nephrolithiasis that resolved completely on
switching 800 mg of indinavir three times daily to indinavir/ritona-
vir (400/100 mg twice daily), leading to a lower indinavir peak
plasma concentration and adequate hydration.
Follow-up parameters [median (interquartile range; number of
samples)] collected during the last 41 months were as follows:
atazanavir plasma concentration at 24 h, 502 ng/mL (330–
631; 8); tenofovir plasma concentration at 24 h, 53 ng/mL
(49–68; 8); variability of atazanavir and tenofovir plasma concen-
trations at 24 h, 16% and 21%, respectively; estimated glomer-
ular filtration rate (according to the Cockcroft–Gault equation),
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